Perspective on human pluripotent stem cell-derived cardiomyocytes in heart disease modeling and repair

Stem cells translational medicine - Tập 9 Số 10 - Trang 1121-1128 - 2020
Qiang Li1,2, Jia Wang3,4, Qiang Wu1,2, Nan Cao3,4, Huang‐Tian Yang1,2
11 CAS Key Laboratory of Tissue Microenvironment and Tumor, Laboratory of Molecular Cardiology Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences (CAS), Shanghai, People’s Republic of China
22 Institute for Stem Cell and Regeneration, CAS, Beijing, People’s Republic of China
33 Program of Stem Cells and Regenerative Medicine, The Fifth Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, People’s Republic of China
44 Key Laboratory for Stem Cells and Tissue Engineering (Sun Yat-Sen University), Ministry of Education, Guangzhou, People’s Republic of China

Tóm tắt

Abstract Heart diseases (HDs) are the leading cause of morbidity and mortality worldwide. Despite remarkable clinical progress made, current therapies cannot restore the lost myocardium, and the correlation of genotype to phenotype of many HDs is poorly modeled. In the past two decades, with the rapid developments of human pluripotent stem cell (hPSC) biology and technology that allow the efficient preparation of cardiomyocytes from individual patients, tremendous efforts have been made for using hPSC-derived cardiomyocytes in preclinical and clinical cardiac therapy as well as in dissection of HD mechanisms to develop new methods for disease prediction and treatment. However, their applications have been hampered by several obstacles. Here, we discuss recent advances, remaining challenges, and the potential solutions to advance this field.

Từ khóa


Tài liệu tham khảo

Hashimoto, 2018, Therapeutic approaches for cardiac regeneration and repair, Nat Rev Cardiol, 15, 585, 10.1038/s41569-018-0036-6

Menasche, 2018, Cell therapy trials for heart regeneration - lessons learned and future directions, Nat Rev Cardiol, 15, 659, 10.1038/s41569-018-0013-0

Kathiresan, 2012, Genetics of human cardiovascular disease, Cell, 148, 1242, 10.1016/j.cell.2012.03.001

Xie, 2014, Small molecules for cell reprogramming and heart repair: progress and perspective, ACS Chem Biol, 9, 34, 10.1021/cb400865w

Sadek, 2020, Toward the goal of human heart regeneration, Cell Stem Cell, 26, 7, 10.1016/j.stem.2019.12.004

Oikonomopoulos, 2018, Pluripotent stem cell-derived cardiomyocytes as a platform for cell therapy applications: progress and hurdles for clinical translation, Mol Ther, 26, 1624, 10.1016/j.ymthe.2018.02.026

Berry, 2019, Convergences of life sciences and engineering in understanding and treating heart failure, Circ Res, 124, 161, 10.1161/CIRCRESAHA.118.314216

Mummery, 2012, Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview, Circ Res, 111, 344, 10.1161/CIRCRESAHA.110.227512

Burridge, 2014, Chemically defined generation of human cardiomyocytes, Nat Methods, 11, 855, 10.1038/nmeth.2999

Lian, 2012, Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling, Proc Natl Acad Sci USA, 109, E1848, 10.1073/pnas.1200250109

Menasche, 2015, Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report, Eur Heart J, 36, 2011, 10.1093/eurheartj/ehv189

Cao, 2013, Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions, Cell Res, 23, 1119, 10.1038/cr.2013.102

Cao, 2015, Generation, expansion, and differentiation of cardiovascular progenitor cells from human pluripotent stem cells, Methods Mol Biol, 1212, 113, 10.1007/7651_2014_119

Rikhtegar, 2019, Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs, and skeletal myoblasts, Biomed Pharmacother, 109, 304, 10.1016/j.biopha.2018.10.065

Halaidych, 2018, Inflammatory responses and barrier function of endothelial cells derived from human induced pluripotent stem cells, Stem Cell Rep, 10, 1642, 10.1016/j.stemcr.2018.03.012

Zhang, 2019, Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis, Circ Res, 125, 552, 10.1161/CIRCRESAHA.119.315491

Zhang, 2019, Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors, Nat Commun, 10, 2238, 10.1038/s41467-019-09831-5

Caspi, 2007, Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts, J Am Coll Cardiol, 50, 1884, 10.1016/j.jacc.2007.07.054

Laflamme, 2007, Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts, Nat Biotechnol, 25, 1015, 10.1038/nbt1327

Laake, 2007, Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction, Stem Cell Res, 1, 9, 10.1016/j.scr.2007.06.001

Chong, 2014, Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts, Nature, 510, 273, 10.1038/nature13233

Liu, 2018, Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates, Nat Biotechnol, 36, 597, 10.1038/nbt.4162

Wang, 2019, Human embryonic stem cell-derived cardiovascular progenitors repair infarcted hearts through modulation of macrophages via activation of signal transducer and activator of transcription 6, Antioxid Redox Signal, 31, 369, 10.1089/ars.2018.7688

Menasché, 2018, Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction, J Am Coll Cardiol, 71, 429, 10.1016/j.jacc.2017.11.047

Zhu, 2018, Lack of remuscularization following transplantation of human embryonic stem cell-derived cardiovascular progenitor cells in infarcted nonhuman primates, Circ Res, 122, 958, 10.1161/CIRCRESAHA.117.311578

Gao, 2018, Relationship between the efficacy of cardiac cell therapy and the inhibition of differentiation of human iPSC-derived nonmyocyte cardiac cells into myofibroblast-like cells, Circ Res, 123, 1313, 10.1161/CIRCRESAHA.118.313094

Mummery, 2018, Perspectives on the use of human induced pluripotent stem cell-derived cardiomyocytes in biomedical research, Stem Cell Rep, 11, 1306, 10.1016/j.stemcr.2018.11.011

Tachibana, 2017, Paracrine effects of the pluripotent stem cell-derived cardiac myocytes salvage the injured myocardium, Circ Res, 121, e22, 10.1161/CIRCRESAHA.117.310803

Shiba, 2014, Electrical integration of human embryonic stem cell-derived cardiomyocytes in a Guinea pig chronic infarct model, J Cardiovasc Pharmacol Ther, 19, 368, 10.1177/1074248413520344

Bellamy, 2014, Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold, J Heart Lung Transplant, 34, 1198, 10.1016/j.healun.2014.10.008

Tomescot, 2007, Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats, Stem Cells, 25, 2200, 10.1634/stemcells.2007-0133

Shiba, 2016, Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts, Nature, 538, 388, 10.1038/nature19815

Laflamme, 2005, Formation of human myocardium in the rat heart from human embryonic stem cells, Am J Pathol, 167, 663, 10.1016/S0002-9440(10)62041-X

Qiao, 2011, Long-term improvement in postinfarct left ventricular global and regional contractile function is mediated by embryonic stem cell-derived cardiomyocytes, Circ Cardiovasc Imaging, 4, 33, 10.1161/CIRCIMAGING.110.957431

Ong, 1733, Mining exosomal microRNAs from human-induced pluripotent stem cells-derived cardiomyocytes for cardiac regeneration, Methods Mol Biol, 2018, 127

Lee, 2017, Comparison of non-coding rNAs in exosomes and functional efficacy of human embryonic stem cell- versus induced pluripotent stem cell-derived cardiomyocytes, Stem Cells, 35, 2138, 10.1002/stem.2669

Kervadec, 2016, Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure, J Heart Lung Transplant, 35, 795, 10.1016/j.healun.2016.01.013

Liu, 2018, Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells, Nat Biomed Eng, 2, 293, 10.1038/s41551-018-0229-7

Kannappan, 2019, Functionally competent DNA damage-free induced pluripotent stem cell-derived cardiomyocytes for myocardial repair, Circulation, 140, 520, 10.1161/CIRCULATIONAHA.119.040881

Yang, 2014, Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes, Circ Res, 114, 511, 10.1161/CIRCRESAHA.114.300558

Jiang, 2018, Maturation of cardiomyocytes derived from human pluripotent stem cells: current strategies and limitations, Mol Cells, 41, 613

Ulmer, 2018, Contractile work contributes to maturation of energy metabolism in hiPSC-derived cardiomyocytes, Stem Cell Rep, 10, 834, 10.1016/j.stemcr.2018.01.039

Poon, 2020, The cell surface marker CD36 selectively identifies matured, mitochondria-rich hPSC-cardiomyocytes, Cell Res, 0, 1

Ronaldson-Bouchard, 2018, Advanced maturation of human cardiac tissue grown from pluripotent stem cells, Nature, 556, 239, 10.1038/s41586-018-0016-3

Funakoshi, 2016, Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes, Sci Rep, 6, 10.1038/srep19111

Kolanowski, 2017, Making human cardiomyocytes up to date: derivation, maturation state and perspectives, Int J Cardiol, 241, 379, 10.1016/j.ijcard.2017.03.099

Zhang, 2018, Can we engineer a human cardiac patch for therapy?, Circ Res, 123, 244, 10.1161/CIRCRESAHA.118.311213

Kadota, 2017, In vivo maturation of human induced pluripotent stem cell-derived cardiomyocytes in neonatal and adult rat hearts, Stem Cell Rep, 8, 278, 10.1016/j.stemcr.2016.10.009

Shadrin, 2017, Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues, Nat Commun, 8, 1825, 10.1038/s41467-017-01946-x

Gao, 2018, Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine, Circulation, 137, 1712, 10.1161/CIRCULATIONAHA.117.030785

Rusinkevich, 2019, Temporal dynamics of immune response following prolonged myocardial ischemia/reperfusion with and without cyclosporine A, Acta Pharmacol Sin, 40, 1168, 10.1038/s41401-018-0197-1

Fan, 2019, Cardiomyocytes from CCND2-overexpressing human induced-pluripotent stem cells repopulate the myocardial scar in mice: a 6-month study, J Mol Cell Cardiol, 137, 25, 10.1016/j.yjmcc.2019.09.011

Saludas, 2019, Long-term engraftment of human cardiomyocytes combined with biodegradable microparticles induces heart repair, J Pharmacol Exp Ther, 370, 761, 10.1124/jpet.118.256065

Ye, 2014, Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells, Cell Stem Cell, 15, 750, 10.1016/j.stem.2014.11.009

Gao, 2017, Myocardial tissue engineering with cells derived from human-induced pluripotent stem cells and a native-like, high-resolution, 3-dimensionally printed scaffold, Circ Res, 120, 1318, 10.1161/CIRCRESAHA.116.310277

Bargehr, 2019, Epicardial cells derived from human embryonic stem cells augment cardiomyocyte-driven heart regeneration, Nat Biotechnol, 37, 895, 10.1038/s41587-019-0197-9

Park, 2019, Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction, Nat Commun, 10, 3123, 10.1038/s41467-019-11091-2

Park, 2019, Insights into the pathogenesis of catecholaminergic polymorphic ventricular tachycardia from engineered human heart tissue, Circulation, 140, 390, 10.1161/CIRCULATIONAHA.119.039711

Tang, 2018, Concise review: is cardiac cell therapy dead? Embarrassing trial outcomes and new directions for the future, Stem Cells Translational Medicine, 7, 354, 10.1002/sctm.17-0196

Li, 2020, Targeted anti–IL-1β platelet microparticles for cardiac detoxing and repair, Sci Adv, 6

Vagnozzi, 2019, An acute immune response underlies the benefit of cardiac stem-cell therapy, Nature, 577, 405, 10.1038/s41586-019-1802-2

Romagnuolo, 2019, Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias, Stem Cell Rep, 12, 967, 10.1016/j.stemcr.2019.04.005

Musunuru, 2018, Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association, Circ Genom Precis Med, 11

Gouadon, 2016, Concise review: pluripotent stem cell-derived cardiac cells, a promising cell source for therapy of heart failure: where do we stand?, Stem Cells, 34, 34, 10.1002/stem.2205

Kawamura, 2016, Cardiomyocytes derived from MHC-homozygous induced pluripotent stem cells exhibit reduced allogeneic immunogenicity in MHC-matched non-human primates, Stem Cell Rep, 6, 312, 10.1016/j.stemcr.2016.01.012

Leung, 2019, Ectopic expression of recipient CD47 inhibits mouse macrophage-mediated immune rejection against human stem cell transplants, FASEB J, 33, 484, 10.1096/fj.201800449R

George, 2019, Antibody conditioning enables MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance, Cell Stem Cell, 25, 185, 10.1016/j.stem.2019.05.018

Carvajal-Vergara, 2010, Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome, Nature, 465, 808, 10.1038/nature09005

Brodehl, 2019, Human induced pluripotent stem-cell-derived cardiomyocytes as models for genetic cardiomyopathies, Int J Mol Sci, 20, 10.3390/ijms20184381

Schwartz, 2001, Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias, Circulation, 103, 89, 10.1161/01.CIR.103.1.89

Terrenoire, 2013, Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics, J Gen Physiol, 141, 61, 10.1085/jgp.201210899

Ma, 2013, Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells, Int J Cardiol, 168, 5277, 10.1016/j.ijcard.2013.08.015

Sun, 2012, Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy, Sci Transl Med, 4, 130, 10.1126/scitranslmed.3003552

Lee, 2019, Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy, Nature, 572, 335, 10.1038/s41586-019-1406-x

Wang, 2014, Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies, Nat Med, 20, 616, 10.1038/nm.3545

Matsa, 2014, Human stem cells for modeling heart disease and for drug discovery, Sci Transl Med, 6, 239, 10.1126/scitranslmed.3008921

Zhao, 2019, A platform for generation of chamber-specific cardiac tissues and disease modeling, Cell, 176, 913, 10.1016/j.cell.2018.11.042

Zuppinger, 2019, 3D cardiac cell culture: a critical review of current technologies and applications, Front Cardiovasc Med, 6, 87, 10.3389/fcvm.2019.00087

Musunuru, 2013, Genome editing of human pluripotent stem cells to generate human cellular disease models, Dis Model Mech, 6, 896

Tang, 2016, Patient-specific induced pluripotent stem cells for disease modeling and phenotypic drug discovery, J Med Chem, 59, 2, 10.1021/acs.jmedchem.5b00789